dorzolamide-timolol-combination and Retinal-Detachment

To determine if topical aqueous suppression affects the duration of intraocular sulfur hexafluoride (SF6) gas tamponade after pars plana vitrectomy.. A prospective randomized controlled trial was conducted on patients undergoing 23-gauge sutured pars plana vitrectomy with air-fluid exchange and 20% SF6 gas tamponade. Eyes were randomly assigned to receive either postoperative topical dorzolamide 2%-timolol 0.5% twice a day or no additional drops (control group). Standard postoperative topical antibiotics and corticosteroids were used by all patients.. A total of 21 patients were recruited for the study. Four were excluded because of noncompliance with use of dorzolamide-timolol. In the remaining 17 patients, 8 were randomly assigned to the dorzolamide-timolol group and 9 to the control group. Topical dorzolamide-timolol drops twice a day did not affect the duration of SF6 gas tamponade after pars plana vitrectomy (17.1 vs. 18.1 days with no drops, P = 0.35). The difference in mean gas duration was -1.0 days with a 95% confidence interval of -3.2 days to 1.2 days. Secondary analyses did not reveal a difference in SF6 duration based on lens status, presence of diabetes or hypertension, vitrectomy versus combined buckle with vitrectomy, or patient age.. Topical aqueous suppression with dorzolamide-timolol does not have a large effect on duration of SF6 gas tamponade after pars plana vitrectomy.

Topics: Administration, Ophthalmic; Aged; Drug Combinations; Endotamponade; Gases; Humans; Middle Aged; Ophthalmic Solutions; Prospective Studies; Retinal Detachment; Retinal Perforations; Scleral Buckling; Sulfonamides; Sulfur Hexafluoride; Thiophenes; Timolol; Vitrectomy

We document the recurrence of a CSMD in a patient subsequent to the instillation of topical ocular hypotensive medications and its resolution on discontinuation of therapy. An independent cause or causes contributing to the development of CSMD other than the use of topical ocular hypotensive medications cannot be ruled out in this case, neither can it be considered dissociated from the use of these drugs. We recommend that patients with VTS, those with a history of CSMD or having developed recurrent episodes of CSMD requiring management with topical ocular hypotensive medications, be cautiously monitored for the possible occurrence or exacerbation of CSMD.

Topics: Administration, Topical; Antihypertensive Agents; Clonidine; Drug Combinations; Drug Therapy, Combination; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Recurrence; Retinal Detachment; Serum; Sulfonamides; Thiophenes; Timolol; Tomography, Optical Coherence; Visual Acuity